diethyl 6-(2-thiophenemethoxy)hexylmalonate | 201734-36-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: diethyl 6-(2-thiophenemethoxy)hexylmalonate
• 英文别名: Diethyl 2-[6-(thiophen-2-ylmethoxy)hexyl]propanedioate
• CAS: 201734-36-3
• 化学式: C₁₈H₂₈O₅S
• 分子量: 356.483
• InChiKey: XZAPIOCJGDTLOP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  24
• 可旋转键数：
  15
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  90.1
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  diethyl 6-(2-thiophenemethoxy)hexylmalonate 在 氢氧化钾 作用下， 以 乙醇 为溶剂， 反应 6.0h， 以79%的产率得到ethyl 6-(2-thiophenemethoxy)hexylmalonate
  参考文献：
  名称：

  Design and Syntheses of 2-Oxiranecarboxylate Derivatives and Their Hypoglycemic Activities

  摘要：

  A series of 2-oxiranecarboxylate derivatives were prepared as carnitine palmitoyl transferase I (CPT-I) inhibitors for the development of new antidiabetic agents. The syntheses and biological activities were reported. The most promising derivative (13b) showed 2.5 times more hypoglycemic activity and 2 times lower acute toxicity compared to Etomoxir ((3)).

  DOI：

  10.3987/com-98-8235
• 作为产物：
  描述：

  1,6-二(甲磺酰基氧基)己烷 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 32.0h， 生成 diethyl 6-(2-thiophenemethoxy)hexylmalonate
  参考文献：
  名称：

  Design and Syntheses of 2-Oxiranecarboxylate Derivatives and Their Hypoglycemic Activities

  摘要：

  A series of 2-oxiranecarboxylate derivatives were prepared as carnitine palmitoyl transferase I (CPT-I) inhibitors for the development of new antidiabetic agents. The syntheses and biological activities were reported. The most promising derivative (13b) showed 2.5 times more hypoglycemic activity and 2 times lower acute toxicity compared to Etomoxir ((3)).

  DOI：

  10.3987/com-98-8235

文献信息

• Oxiran carboxylic acids for the treatment of diabetes
  申请人：——

  公开号：US20020198382A1

  公开（公告）日：2002-12-26

  The invention relates to novel arylalkyl- or aryloxyalkyl-substituted oxiranecarboxyclic acids of the general formula I 1 in which Ar, R 3 , Y and n are as defined in the description, and also to medicaments comprising them and to their use for the treatment and prophylaxis of the disorders mentioned in the description [in claim 4] which are caused by disturbances of glucose and/or lipid metabolism, such as, for example diabetes type 2, and other insulin-resistant conditions.

  本发明涉及通式 I 的新型芳烷基或芳氧基烷基取代的环氧乙烷羧酸 1 其中 Ar、R 3 、Y 和 n 如描述中所定义，本发明还涉及由它们组成的药物，以及它们用于治疗和预防描述 [在权利要求 4] 中提到的疾病，这些疾病是由葡萄糖和/或脂质代谢紊乱引起的，例如 2 型糖尿病和其他胰岛素抵抗性疾病。
• US6013666A
  申请人：——

  公开号：US6013666A

  公开（公告）日：2000-01-11
• [EN] OXIRANE CARBOXYLIC ACID DERIVATIVE AND ITS MANUFACTURING METHOD<br/>[FR] DERIVE D'ACIDE CARBOXYLIQUE D'OXIRANE ET SON PROCEDE DE FABRICATION
  申请人：JEW, Sang, Sup

  公开号：WO1998000422A1

  公开（公告）日：1998-01-08

  (EN) This invention relates to a novel oxirane carboxylic acid derivative and thereof manufacturing method. Based on thereof mechanism to inhibit the CPT I, oxirane carboxylic acid derivative of this invention has blood glucose lowering effects so that the derivative may be effectively used as an antidiabetic agent having remarkable antidiabetic activity and less side effects.(FR) Cette invention concerne un nouveau dérivé d'acide carboxylique d'oxirane et son procédé de fabrication. Sur la base de son mécanisme qui inhibe CPT I, le dérivé d'acide carboxylique d'oxirane a la propriété de réduire le taux de glucose dans le sang de sorte qu'il puisse être utilisé efficacement comme agent antidiabétique dont l'activité antidiabétique est remarquable et présente des effets secondaires réduits.
• Design and Syntheses of 2-Oxiranecarboxylate Derivatives and Their Hypoglycemic Activities
  作者：Sang-sup Jew、Eun-kyung Kim、Sun-mi Je、Long-Xuan Zhao、Hyung-ook Kim、Hyeung-geun Park、Kwang-ho Ko、Won-ki Kim、Hwa-Jung Kim、Jae Hoon Cheong、Eung-Seok Lee

  DOI：10.3987/com-98-8235

  日期：——

  A series of 2-oxiranecarboxylate derivatives were prepared as carnitine palmitoyl transferase I (CPT-I) inhibitors for the development of new antidiabetic agents. The syntheses and biological activities were reported. The most promising derivative (13b) showed 2.5 times more hypoglycemic activity and 2 times lower acute toxicity compared to Etomoxir ((3)).